Document ID: chunk:federal_register_of_legislation:F2024C00658:reg:9:p7
Version: federal_register_of_legislation:F2024C00658
Segment Type: reg
Provision Reference: reg 9 (pt 7/7)
Character Range: 25397–27120

at least 21 days within the 2 months before clinical onset;
(69)      taking a systemic vascular endothelial growth factor (VEGF) inhibitor or monthly intra-vitreous injections of a VEGF inhibitor within the 4 months before clinical onset;
Note: Vascular endothelial growth factor (VEGF) inhibitors include monoclonal antibodies, such as bevacizumab; fusion molecules such as aflibercept; and tyrosine kinase inhibitors, such as axitinib, cabozantinib, lenvatinib, nintedanib, pazopanib, sorafenib, sunitinib and vandetanib. Systemic VEGF inhibitors are used in the treatment of several cancers, and other indications such as interstitial lung disease. Intra-vitreous injections of VEGF inhibitors (such as aflibercept, bevacizumab, ranibizumab) are used mostly in the treatment of age-related macular degeneration, macular oedema due to diabetes mellitus or retinal vein occlusion and choroidal neovascularisation.
(70)      taking alemtuzumab within the 30 days before clinical onset;
Note: Alemtuzumab is usually used for treatment of multiple sclerosis or chronic lymphocytic leukaemia.
(71)      taking ponatinib on more days than not for 2 weeks within the 30 days before clinical onset;
Note: Ponatinib is usually used for treatment of chronic myeloid leukaemia or acute lymphoblastic leukaemia.
(72)      taking a thalidomide analogue within the 30 days before clinical onset;
Note: a thalidomide analogue includes thalidomide, lenalidomide and pomalidomide and are used in the treatment of multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma and erythema nodosum leprosum.
(73)      inability to obtain appropriate clinical management for cerebrovascular accident (stroke) prior to clinical worsening.